VisionQuest Biomedical is structured around development and application of the advanced medical imaging technology - developed by the firm's founder - designed to enhance detection and diagnosis of chronic diseases, such as diabetic retinopathy, age related macular degeneration and glaucoma. Technologies include an adaptive optics fundus imager, an optical functional imager of the retina, and software for automatic detection of retinal lesions in patients with diabetic retinopathy, age-related macular degeneration (ARMD), and glaucoma. With the focus on creating low-cost, portable imaging technology for screening high-risk populations for glaucoma, diabetic retinopathy, and ARMD, the medical image analysis and optical imaging technology being developed by VisionQuest also have other applications in the medical industry such as specialized MRI scanning methods. VisionQuest's products include Diabetic Retinopathy (DR) Risk Analyzer, the CVD Retinal Vessel Analyzer, NeuroTherm and the firms flagship product, EyeStar. The EyeStar System is an automated eye-disease screening system package, which scans individuals for various diseases of the eye and provides seamless integration of computer-assisted eye-disease screening with normal clinic workflow. Being used first on individuals with diabetic retinopathy, which impacts 24 million U.S. residents, the technology - both easy to use and non-invasive - could potentially prevent early loss of vision for millions of diabetics.
